Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC
Why cancer care is personal for us Why cancer care is personal for us At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Dedifferentiated liposarcoma (DDLPS) Dedifferentiated liposarcoma (DDLPS) An aggressive subtype of a category of cancers called soft tissue sarcoma (STS). DDLPS has a poor prognosis and limited treatment options.
Groundbreaking oncology research zongertinib Groundbreaking oncology research zongertinib Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio